OXIGENE, INC.

Company

Oncotelic Therapeutics, Inc.

Filed

October 30, 2008

Period of Report

December 9, 2008

Accession Number

0000950135-08-006798

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →